Melanotropin Receptors Demonstrated In Situ in Human Melanoma

Jeffrey B. Tatro,* Michael Atkins,1 James W. Mier,† Sverrir Hardarson,§ Hubert Wolfe," Thomas Smith,1 Margaret L. Entwistle,* and Seymour Reichlin*

Divisions of*Endocrinology and 1Hematology-Oncology, Department of Medicine, and Departments of 3Pathology and 4Surgical Oncology, New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts 02111

Abstract

Although some cultured human melanoma cell lines are responsive to melanotropins (melanocyte-stimulating hormones [MSH]), the prevalence and tissue distribution of MSH receptors in melanoma are unknown. We report here the use of an in situ binding technique to demonstrate specific MSH receptors in surgical specimens of human melanoma. The distribution and binding properties of specific MSH binding sites were determined by autoradiography and image analysis after incubation of frozen tumor tissue sections with a biologically active, radiolabeled analogue of alpha-MSH, [125I]iodo-Nle4, D-Phe2-alpha-MSH ([125I]NDP-MSH). In melanoma specimens from 11 patients, 3 showed high levels of specific binding, 5 showed low levels, and in 3 patients specific binding of [125I]NDP-MSH was not detectable. Specific MSH binding sites were present in melanoma cells, but not in adjacent connective or inflammatory tissues. Melanotropins, including alpha-MSH, NDP-MSH, and ACTH, inhibited [125I]NDP-MSH binding in a concentration-dependent manner, whereas unrelated peptides (somatostatin and substance P) did not. The apparent affinity of alpha-MSH for this binding site was in the nanomolar range (EC50 = 2 × 10^-9 M for inhibition of [125I]NDP-MSH binding in situ), similar to that recently described for the murine melanoma receptor. In one patient, analysis of multiple intratumor samples and tumors excised on three separate occasions revealed high levels of specific MSH binding in all samples. These results suggest that endogenous melanotropins may modulate the activities of human melanoma cells in vivo. (J. Clin. Invest. 1990. 85:1825-1832.)

Introduction

Since the discovery that mouse melanoma cell activities are influenced by melanotropins (melanocyte-stimulating hormones [MSH])1) (1), much interest has been focused on the biological actions and potential clinical value of MSH in human melanoma. Several treatment strategies are currently being developed that aim to exploit the interaction of alpha-MSH with its receptors on melanoma cells. These agents are designed to kill the cells either directly, using MSH-toxin hybrid molecules (2, 3), or indirectly, by targeting the cells for T cell–mediated destruction using MSH (anti-CD3 receptor) conjugates (4). The clinical potential of these approaches is critically dependent on the presence of functional alpha-MSH receptors on human melanoma cells in vivo. However, while animal melanoma cell lines have long been known to respond to MSH (1) and have recently been shown to express MSH receptors in vitro (5–7) and in situ (5), the frequency with which MSH receptors are expressed in human melanomas is unknown.

Metabolic effects of MSH have been detected in some cultured human melanoma cell lines (8, 9). Earlier attempts to detect alpha-MSH binding sites in cultured human melanoma cells were inconclusive (9, 10), but one group has recently confirmed the presence of an MSH binding protein with the use of biologically active MSH tracer peptides (11, 12). Nevertheless, it is not clear to what extent the behavior of tumor cells in culture reflects that in vivo, since cultured melanocytic cells have been shown to express an altered profile of cell surface proteins such as growth factor receptors, as compared with the corresponding cells in situ (13).

To assess the potential biological roles of endogenous melanotropins in human melanoma and the potential therapeutic value of MSH receptor-targeted agents, we designed these studies to determine the presence or absence and the binding properties of melanotropin receptors in human melanoma cells in situ. We have recently developed methods for the characterization of MSH receptors in cultured B16 mouse melanoma cells in vitro and in tumor tissue in situ (5, 14) using a radiolabeled MSH tracer that has full biological activity and potency (14), and is known to detect functional MSH receptors (5). The results, recently presented in preliminary form (15), indicate that melanoma cells of some metastatic tumors express MSH receptors, which has implications for the basic biology of melanoma as well as for the therapeutic utility of MSH receptor-targeted agents.

Methods

Patients and tumor specimens. Tumor specimens were obtained from patients undergoing therapeutic excision of known or suspected melanoma metastases. 12 patients were studied (51–77 yr of age; 7 female, 5 male). Tumors of 11 patients were confirmed histologically to be metastatic melanomas; one was a leiomyoma. Tissues were placed in 0.9% NaCl and dissected free of fat, connective tissue, and accessible necrotic areas on ice within 3 h of excision. Cubes of tissue were dissected from up to five areas representative of the gross morphology of each tumor and placed in chilled OCT compound (Miles Laboratories Inc., Naperville, IL), frozen at –23°C, and stored in sealed bags at –70°C.

This work was presented in part at the Annual Meeting of the Endocrine Society, June 1989, in Seattle, WA.

Address reprint requests to Dr. Jeffrey B. Tatro, Endocrinology Division, Box 268, New England Medical Center Hospitals, 750 Washington Street, Boston, MA 02111.

Received for publication 20 November 1989 and in revised form 6 February 1990.

1. Abbreviations used in this paper: MSH, melanocyte-stimulating hormone; NDP-MSH, Nle4, D-Phe2-alpha-MSH.

0021-9738/90/06/1825/08 $2.00
Volume 85, June 1990, 1825–1832

Melanoma Melanocyte-stimulating Hormone Receptors 1825
Peptides. Alpha-MSH and Nle5, D-Phe1-α-MSH (NDP-MSH) were obtained from Bachem Inc. (Torrance, CA) and Peninsula Laboratories, Inc. (Belmont, CA). The respective peptides from these two sources have proven consistently comparable in potency in RIA and mouse melanoma binding assays and bioassays (Tatro, J. B., unpublished observations). Synthetic human ACTH1-39 and somatostatin were obtained from Peninsula Laboratories, Inc. Substance P was obtained from Boehringer Mannheim GmbH (Mannheim, FRG).

Preparation of 125I-NDP-MSH. NDP-MSH was iodinated and purified as described (14). Briefly, 4 μg peptide was iodinated using Enzymobeads (Bio-Rad Laboratories, Richmond, CA) and purified by reverse-phase chromatography. Fractions were pooled from the portion of the eluted peak showing greatest immunoreactivity and specific activity (typically 1.2–2.0 × 106 Ci/mol). This material has consistently shown biological activity (stimulation of melanogenesis) virtually identical to that of uniodinated NDP-MSH in B16 mouse melanoma cells (14).

In situ binding studies. Serial slide-mounted, dried, unfixed tissue sections were preincubated for 15 min at 23°C in a buffer consisting of 50 mM Tris-HCl, 140 mM NaCl, 2.5 mM CaCl2, and 1.2 mM MgCl2, pH 7.2. Matched sets of serial sections were then incubated for 60 min in a similar buffer with the addition of BSA (0.25%), ascorbic acid (0.6%), aprotinin (500 KIU/ml), and [125I]-NDP-MSH (2.5–5.0 × 106 cpm/ml; ~ 0.15–0.3 nm) in the presence or absence of unlabeled peptides. To terminate binding reactions, slides were washed in ice-cold buffer (10 mM sodium phosphates, 154 mM NaCl, and 1.2 mM MgCl2, pH 7.2), dried under a cold air stream, and fixed in hot paraformaldehyde vapors under vacuum (5, 16). After ventilating the slides in a fume hood overnight, autoradiographic detection of 125I-NDP-MSH binding was performed by one or both of two methods.

For assessment of histological patterns of binding site distribution by bright- and dark-field microscopy, matched pairs of serial sections were coated with NTR2 liquid photographic emulsion (Eastman Kodak Co., Rochester, NY) diluted 1:1 with 0.6 mM ammonium acetate, exposed in the dark at 4°C for 8–14 d, developed for 2.5 min in D19 developer (Eastman Kodak Co.), and counterstained with hematoxylin-eosin or methyl green. In 10 of 11 cases a second set of sections was applied directly to x-ray film (IlfordUltrofilm; LKB Instruments, Inc., Gaithersburg, MD), and exposed for 7–21 d at room temperature. The films were used for quantitative comparisons of relative binding levels under different conditions and in different patients by means of image analysis. In control experiments, tissue sections that were incubated in the absence of tracer did not produce signals above the non-tissue background level, either in liquid emulsions or on x-ray films. This was true even for samples containing highly melanized areas, thus ruling out chemography as an artificial source of signal.

Image analysis. Video images of film autoradiographs were digitized using a Gordon transilluminator and EyeCom model 7005V image scanner (Spatial Data Systems, Inc.; Goleta, CA), and analyzed using a VAX 11/780 computer, Gould/DeAnza ID5424 color display/image processor, and the DISPEX program of the Image Analysis Laboratory, Tufts-New England Medical Center. For each film autoradiogram analyzed, mean optical densities of replicate square fields were obtained for background (nontissue) areas immediately surrounding the area of film overlying the tissue (two to four readings), and for film areas overlying contiguous tissue areas (two to five readings per section). In specimens heterogeneous with respect to histomorphological tissue types, only contiguous areas composed primarily of viable melanoma cells were analyzed. The relative intensity of peptide-specific [125I]-NDP-MSH binding in a given tissue was then calculated according to the formula:

\[ \text{OD}_{\text{peptide}} = (\text{OD}_{\text{dark}} - \text{OD}_{\text{background}}) - (\text{OD}_{\text{blank}} - \text{OD}_{\text{background}}) \]

where OD = mean optical density, expressed as a value on the 256-level gray scale; ODpeptide = MSH-induced decrease in OD, used as an index of binding intensity; tiss = tissue; bkg = background; control = incubated with tracer only; and peptide = incubated with tracer plus unlabeled competing peptide. For each variable studied, this analysis was performed on one or two sections per slide and one to three slides per experimental condition studied. In separate experiments, using a series of [125I]-NDP-MSH radioactivity concentration reference standards prepared in liver paste and processed comparably to tumor specimens (17), it was determined that the concentration–response relationship for film OD response to increasing concentrations of tissue radioactivity was approximately linear within the observed range of OD.

Specimens were designated as showing detectable or undetectable specific binding according to the following criteria. In the presence of 10−6 M alpha-MSH, a mean decrease in tissue-bound radioactivity giving a change in OD of > 3 gray levels in any given tissue specimen, an amount easily perceptible by eye, was considered a positive indication of the presence of specific MSH binding sites in the respective patients. Specimens that were classified as showing undetectable specific binding gave an alpha-MSH-induced change in integrated OD of ≤ 1 gray level. In two patients the apparent absence of specific [125I]-NDP-MSH binding in liquid emulsion-coated tissue sections was verified by performing blind, replicate counts of silver grains on dark-field photomicrographs, rather than by analysis of digitized x-ray film images (original magnification ×108, four fields per photomicrograph, three photomicrographs per tissue section; data not shown).

Statistics. Data are presented as means±SEM unless indicated otherwise. Differences in means between patient groups and experimental conditions were tested for significance using analysis of variance for repeated measures and t tests (18). Results of competitive binding experiments were analyzed using the RIA-AID computer program (Robert Maciel Associates, Inc., Arlington Heights, MA).

Results

Demonstration and distribution of MSH binding sites in tumor tissue. Autoradiographic studies of [125I]-NDP-MSH binding in situ in tumor tissue sections showed that specimens of most patients contained specific MSH binding sites. Tracer binding was distributed in a heterogeneous pattern that was highly correlated with tissue morphology (Figs. 1 and 2). Specific binding of tracer, indicated by its inhibition in the presence of 10−6 M alpha-MSH, was restricted to melanoma cells. Specific binding was not detectable in connective tissue (Fig. 1). Areas containing inflammatory cells or necrosis showed high levels of tracer localization, but of a type that was nonspecific, as indicated by its persistence in the presence of alpha-MSH (Figs. 1 and 2). While many of the cells showing high nonspecific binding in emulsion-coated sections were pigmented (Fig. 1), those that were clearly identifiable as to cell type were melanin-laden macrophages. No tracer binding was observed in normal lymphoid tissue, which was studied in uninvolved lymph nodes of a patient with lymph node melanoma metastases.

Time course of binding. Specific binding of [125I]-NDP-MSH to melanoma cells in situ was time dependent, reaching half-maximal and maximal levels at ~ 45 min and 2–4 h, respectively (Fig. 3). Further studies were therefore carried out using 2-h incubations.

Peptide specificity of melanotropin binding sites. To assess the melanotropin specificity of melanoma MSH binding sites and to test whether they bind melanotropins with high affinity, we next determined the potencies of a series of melanotrophic peptides, NDP-MSH, alpha-MSH, and ACTH, in competing with [125I]-NDP-MSH for binding. Each of the three melanotro-
tropins tested inhibited tracer binding to melanoma cells in a concentration-dependent fashion (Fig. 4). Alpha-MSH and NDP-MSH were of comparable potency overall (approximate EC₅₀ = 1–2 × 10⁻⁹ M) in inhibiting [¹²⁵I]NDP-MSH binding (Fig. 4 A), whereas ACTH was less potent (Fig. 4 B). In contrast, the nonmelanotropic peptides substance P (10⁻⁹ M) and somatostatin (10⁻⁶ M), used as controls, did not inhibit tracer binding to tumor cells in tissue sections of the same series (Table I). None of the tested peptides inhibited tracer localization in inflammatory tissue.

**Prevalence of MSH receptor expression in metastatic melanoma patients.** To determine the prevalence of specific melanotropin binding site expression, the relative intensity of specific binding in different patients was assessed by image analysis of film autoradiograms. The data were obtained from three separate experiments. In each experiment, melanoma specimens of known receptor-positive patients, and in some cases specimens of known receptor-positive mouse melanomas as well (5), were tested. This provided positive controls for each experiment and allowed for comparative assessment of the relative binding intensities in different patients.

Metastatic melanoma specimens from 8 of 11 patients showed some degree of specific [¹²⁵I]NDP-MSH binding. A subgroup of three patients showing relatively greater specific binding of [¹²⁵I]NDP-MSH binding was classified as having high-level receptor expression, while the remaining subgroup of five receptor-positive patients was classified as having low-level receptor expression (Table II). Representative x-ray film autoradiograms of tissue specimens showing high and low specific binding of [¹²⁵I]NDP-MSH are shown in Fig. 5. The greater responses in the high-level subgroup were associated with both a greater percentage inhibition of total tracer bind-
ing in the presence of alpha-MSH (Table II) and higher absolute binding levels (e.g., Figs. 2 and 5, A and B) than those observed in the low-level subgroup (Fig. 5, C and D). Metastatic melanomas of three patients did not show detectable specific binding (Table II). A specimen of leiomyoma did not show detectable binding. The leiomyoma and one of the receptor-negative melanoma specimens were analyzed by performing replicate counts of silver grains on liquid emulsion-coated slides, rather than by image analysis of film autoradiograms (see Methods).

In one patient showing high levels of specific $^{[125]}$NDP-MSH binding, tissue specimens obtained from five different sites within one large tumor, and also from tumors excised on a total of three separate occasions, were tested. All samples from this patient showed specific $^{[125]}$NDP-MSH binding. When studied within a single experiment, specific binding in

Figure 2. Melanoma cell-specific localization of stereospecific $^{[125]}$NDP-MSH binding sites in serial sections of metastatic tumor showing mixed morphology. A and B, x-ray film autoradiograms of serial sections exposed to $^{[125]}$NDP-MSH only (A) and to $^{[125]}$NDP-MSH plus 1 $\mu$M alpha-MSH (B). C, Histological appearance of area corresponding to left-hand portion of each autoradiogram, which shows marked inhibition of binding in the presence of alpha-MSH. This region contains primarily melanoma cells. D, Histological appearance of tissue area corresponding to right-hand portions of autoradiograms, which show only nonspecific tracer uptake as indicated by its persistence in the presence of alpha-MSH. This region is composed of inflammatory tissue. Hematoxylin and eosin, original magnification $\times 200$. 

Tatro, Atkins, Mier, Hardarson, Wolfe, Smith, Entwistle, and Reichlin
the multiple intratumor specimens varied over a 10-fold range of intensity (examples shown in Figs. 2 and 5, A and B), but high-level expression was observed in all the specimens.

Discussion

These studies demonstrate for the first time that specific melanotropin binding sites are expressed in human melanoma in situ. The evidence supports the hypothesis that these binding sites represent functional receptors since they exhibit high affinity, melanotropin specificity, and tissue specificity (i.e., localization of specific binding sites in melanoma cells rather than in associated nontumor tissues). These properties likewise have been demonstrated recently for the functional MSH receptors of highly MSH-responsive B16 mouse melanoma cell sublines (5, 6).

The presence of melanotropin receptors on melanoma cells is of interest both because of the potential role of endogenous melanotropins in melanoma growth or metastasis, and also because the MSH receptor may represent a relatively tissue-specific surface protein that may be used in targeting melanoma cells for delivery of clinically useful antineoplastic substances. Among different patients, levels of receptor expression varied from undetectable to intense, which may account in part for the reported heterogeneity in cultured human melanoma cell responses to alpha-MSH (8). Tumors removed from one patient on three separate occasions consistently showed high levels of specific MSH binding, suggesting some degree of homogeneity of receptor expression within tumor deposits of an individual patient.

Although melanotropin responsiveness and MSH receptors in cultured mouse melanoma cell lines have been extensively studied (1, 5–7, 14, 19), the actions of melanotropins in human melanoma are poorly understood. Varying effects of MSH on cultured human melanoma cell tyrosinase activity (8, 9) have been reported. MSH also induces cytoplasmic granule accumulation (20) and stimulates cyclic AMP accumulation in some human melanoma cultures (9) as well as in normal melanocytes (21). Characterization of human MSH receptors has been impossible until very recently, since valid methodologies for their detection have been unavailable. In earlier studies using either immunocytochemical methods (9) or radiolabeled alpha-MSH (10), MSH binding was detected, but the reports failed to document whether the binding was specific (9) or whether the MSH tracer was biologically active (10). More recently, a specific MSH binding protein has been detected in cultured human cell lines with the use of biologically active photolabeled (11) and radiolabeled (12) alpha-MSH derivatives.

Like the MSH receptor of B16 mouse melanoma cells (5–7) and tumors (5), that of human melanomas in situ shows high apparent affinities for melanotropins (nanomolar range). The relative potencies of the peptides in human melanoma

Table I. Peptide Specificity of MSH Binding Sites in Metastatic Melanoma

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Concentration</th>
<th>n</th>
<th>% Inhibition of control tracer binding in situ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alpha-MSH</td>
<td>10^(-10)</td>
<td>3</td>
<td>64.4±14.0*</td>
</tr>
<tr>
<td>Substance P</td>
<td>10^(-8)</td>
<td>3</td>
<td>-23.3±17.9</td>
</tr>
<tr>
<td>Somatostatin</td>
<td>10^(-6)</td>
<td>3</td>
<td>-3.5±9.8</td>
</tr>
</tbody>
</table>

* P = 0.044 vs. control.

Table II. Frequency of Expression of Specific MSH Binding Sites in Human Metastatic Melanoma

<table>
<thead>
<tr>
<th>Relative intensity of specific binding of [125I]-NDP-MSH</th>
<th>No. of cases</th>
<th>% Inhibition of control tracer binding by alpha-MSH</th>
</tr>
</thead>
<tbody>
<tr>
<td>High</td>
<td>3</td>
<td>63.6±6.6*</td>
</tr>
<tr>
<td>Low</td>
<td>5</td>
<td>27.6±4.4*</td>
</tr>
<tr>
<td>Undetectable</td>
<td>3</td>
<td>6.0</td>
</tr>
<tr>
<td>Total</td>
<td>11</td>
<td></td>
</tr>
</tbody>
</table>

* P = 0.012 vs. “Low” subgroup. In the undetectable subgroup x-ray autoradiograms were available for only two patients; the third was analyzed by grain counts in liquid emulsion-coated slides.

Melanoma Melanocyte-stimulating Hormone Receptors

1829
tissues (NDP-MSH = alpha-MSH ≥ ACTH) are not as clearly distinct as those (i.e., NDP-MSH > alpha-MSH > ACTH) reported in murine B16 melanoma cells (5, 6) and tissue sections (5); however, firm conclusions regarding these properties will require studies of additional patients to rule out differences attributable to receptor heterogeneity of melanoma tumor populations (12).

While we have recently shown that MSH receptors are widely distributed in vivo in rodents (14), it is not known whether cells of nonmelanocytic tissues of humans express MSH receptors. In mice, alpha-MSH has immunomodulatory effects on certain lymphoid targets, whereas NDP-MSH does not (22, 23). This suggests that multiple melanotropin receptor subclasses may exist, since NDP-MSH is a superpotent melanotropin agonist in melanocytic cells (24). Accordingly, lymphoid tissues of normal mice or rats show undetectable or very low specific uptake of [125I]NDP-MSH in vivo (14). In a patient having melanoma metastases of lymph nodes, uninvolved lymph nodes showed no evidence of tracer binding, suggesting that normal human lymphoid cells likewise do not express receptors recognizing NDP-MSH. Areas heavily infiltrated by inflammatory cells showed only nonspecific binding of [125I]NDP-MSH, which was also observed in necrotic tissue and is most likely attributable to proteolytic degradation of the tracer. The present results do not rule out the potential presence of melanotropin receptors in occasional inflammatory cells, which may be obscured by nonspecific binding in neighboring cells, nor do they exclude the possibility that occasional melanoma cells may exhibit high levels of nonspecific binding. Nevertheless, where histological identification of cell types was possible in the frozen sections, specific binding was restricted to melanoma cells, indicative of a high degree of cell-type specificity of MSH receptor expression.

The presence of MSH receptors in melanoma raises the possibility that the activities of melanoma cells in vivo may be modulated by endogenous melanotropins. Recent studies of cultured mouse melanoma cells are suggestive of a role of melanotropins in metastasis (25–27), control of cell shape (28), and growth (29–32). Alpha-MSH also stimulates proliferation in A375 human melanoma cells (26), in a panel of human melanoma cell lines (33), and in cultured normal human melanocytes (34). It will therefore be of interest to determine

Figure 5. Representative x-ray film autoradiograms of tumor specimens showing high (A and B) and low (C and D) levels of specific [125I]-NDP-MSH binding in situ. Autoradiograms of serial sections exposed to [125I]NDP-MSH only (A and C) and to [125I]NDP-MSH plus 1 μM alpha-MSH (B and D). All specimens were composed primarily of melanoma cells. Area corresponding to the leftmost portions of autoradiograms in A and B also contained numerous pigmented cells; those that were identifiable histologically were macrophages showing typical nonspecific binding.
whether the level of expression of MSH receptors is related to the stage of tumor progression and/or the degree of aggressiveness of metastasis in melanoma.

In postulating a role of endogenous melanotropins in control of melanoma cell behavior, it is implicit that tumor cells must be exposed to melanotropins in vivo. In fact, the gene encoding the melanotropin precursor, proopiomelanocortin, is expressed in diverse nonpituitary sites, including lymphoid cells and malignant tumors (35–37). Thus, although alpha-MSH and ACTH normally circulate in the blood of humans at only low picomolar concentrations (37, 38), locally produced melanotropins may have significant biological effects. Full assessment of the potential roles of endogenous melanotropins will require determination of which additional processed forms of MSH are present locally or in the circulation, and testing of their effects in melanoma bioassay systems.

The actions of endogenous melanotropins on melanoma may be modulated by interactions with cytokines and the local environment. Interferons, which are present locally and may participate in immune responses to melanoma (39), enhance MSH responses and receptor expression in mouse melanoma cells (40). Moreover, the actions of IL-1, a cytokine that is directly toxic to melanoma cells (41), are antagonized by alpha-MSH in multiple target tissues (18, 19, 42), possibly through a postreceptor mechanism (43). The presence of melanotropin receptors in melanoma thus raises the possibility that melanotropins may affect melanoma cell survival by modulating the actions of cytokines on melanoma cells. Conversely, epidermal-derived thymocyte activating factor, a cytokine-like factor in skin which is highly related to IL-1 (44), antagonizes MSH action in S91 mouse melanoma cells (45). In mouse melanoma cells laminin (46) and collagen (30) augment responsiveness to MSH, suggesting a role of the extracellular matrix in controlling melanotropin responsiveness. Together, the available evidence suggests that melanoma cells may be influenced in vivo by complex and bidirectional interactions between melanotropins, substratum, and immune mediators produced in lymphoid cells and skin, a feature not predicted from earlier in vitro studies.

Several groups have undertaken the development of MSH receptor-targeted agents as potential therapeutic tools for treatment of malignant melanoma (2–4). The present results support the premise of these strategies, since the majority of human metastatic melanomas appear to express detectable specific binding sites, but also indicate that some patients would not be candidates for these therapies. Since MSH receptors are found in some tumors but not in all, the in situ binding assay may be an effective method with which to evaluate patients as candidates for treatment with MSH-linked hybrid therapeutic agents, and to identify other potential sites of toxicity. In situ localization is critical, since the nonspecific binding associated with necrotic and inflammatory tissues may obscure the presence of specific MSH receptors if specimens are assayed by other methods.

In summary, the detection of specific melanotropin receptors in metastatic melanoma in situ raises new questions about the biological roles of proopiomelanocortin-derived peptides in human melanoma. It also increases the likelihood that hybrid MSH-linked therapeutic agents would be useful in the treatment of certain melanoma patients, and provides a potential approach for screening of candidate patients for such therapies. It will be of interest to determine whether normal epidermal melanocytes and cells of other stages of melanocytic tumor progression, such as nevus melanocytes and primary melanoma (13), share the property of MSH receptor expression, and to define the factors that regulate receptor expression and function.

Acknowledgments

This work was supported by National Institutes of Health grants R01-MH-44694-01 (to Dr. Tatro), R01-DK-16884-17 (to Dr. Reichlin), and RR-00054, and by American Cancer Society grant RD-285 (to Dr. Tatro).

We thank Dr. Ronald Lechan and Dr. Stephen Naber for helpful discussions, and Dr. Debbie Beasley for reviewing the manuscript.

References


Melanoma Melanocyte-stimulating Hormone Receptors 1831


